ENTRUST-AF PCI Score (CHA2DS2-VASc & HAS-BLED) Calculator

Age (years)

Sex

Congestive heart failure / Left ventricular dysfunction

Hypertension (history of treated hypertension)

Diabetes mellitus

Prior stroke / TIA / thromboembolism

Vascular disease (prior MI, PAD, or aortic plaque)

Abnormal renal function (dialysis, transplant, or creatinine > 200 µmol/L)

Abnormal liver function (chronic hepatic disease / biochemical evidence)

Prior major bleeding or predisposition to bleeding

Drugs predisposing to bleeding (antiplatelet agents, NSAIDs) or concomitant use

Alcohol use (>8 drinks/week)

References and context
The ENTRUST-AF PCI randomized trial and its prespecified analyses inform antithrombotic choices for AF patients undergoing PCI. Key publications: Vranckx P, et al. ENTRUST-AF PCI (Lancet 2019) — trial report; prespecified analyses and subgroup reports are available in subsequent journal publications. Clinicians should combine the trial evidence with individual CHA₂DS₂-VASc and HAS-BLED assessment when deciding antithrombotic regimens after PCI.

Selected references:
Vranckx P, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335–1343.
Vranckx P, et al. Prespecified analyses of ENTRUST-AF PCI: clinical predictors and subgroup outcomes. Eur Heart J. (analysis).
Additional reviews and subanalyses of AF+PCI populations and bleeding/ischemic predictors also provide context for risk stratification and therapy selection.